Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine Maintenance in Early Stage TNBC
NCT07143097Phase 2Completed
- Sponsor
- Beni Suef University
- Start
- Nov 2021
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in triple-negative breast cancer (TNBC), sponsored by Beni Suef University. Started Nov 2021; status: completed.
02
Drugs
capecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07143097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07143097.